Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer
This study has been completed.
Sponsor:
Predictive Biosciences
Information provided by:
Predictive Biosciences
ClinicalTrials.gov Identifier:
NCT00975455
First received: September 10, 2009
Last updated: June 7, 2011
Last verified: November 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate subjects with gross or microscopic hematuria undergoing scheduled cystoscopy to determine the absence or presence of bladder cancer.
| Condition |
|---|
|
Microscopic or Gross Hematuria |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Phase 3 Study of Hematuria Evaluation |
Resource links provided by NLM:
Further study details as provided by Predictive Biosciences:
Primary Outcome Measures:
- To establish the performance characteristics of the Predictive Biosciences Assay relative to the cystoscopy results for subjects undergoing evaluation for the referral diagnosis of gross or microscopic hematuria [ Time Frame: Initial Visit only ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To establish the performance characteristics of the PB assay relative to urine cytology results for subjects undergoing evaluation for the referral diagnosis of gross or microscopic hematuria. [ Time Frame: Initial Visit ] [ Designated as safety issue: No ]
Biospecimen Description:
urine sample
| Estimated Enrollment: | 1400 |
| Study Start Date: | July 2009 |
| Study Completion Date: | January 2011 |
| Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Subjects with hematuria |
Eligibility| Ages Eligible for Study: | 45 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
Subjects will be selected from Urology and Oncology practices.
Criteria
Inclusion Criteria:
- For those subjects for whom there is no family history of bladder cancer or less than a 20 pack year history of cigarette smoking, subject must be 50 or older.
- Subject's age can be lowered to 45 or older if there is a family history of bladder cancer and/or a 20 or greater pack history of cigarette smoking.
- Subject must have an intact bladder
- Subject must be scheduled to have a cystoscopy to screen for transitional call bladder cancer due to the finding of hematuria.
- Subject must be able to provide a minimum of 25 mL of urine for study purposes.
- Urine samples must be available prior to cystoscopy, bladder biopsy, and TUR.
- Subjects must be willing to sign an Institutional Review Board approved written informed consent prior to any study related procedures being performed.
Exclusion Criteria:
- Subject had a history or current diagnosis of any basal or squamous cell cancer.
- Subject had a known diagnosis of any autoimmune disease.
- Subject had known diagnosis of HIV, HCV or HBV
- Subject had disclosed voluntarily history of or current infection with TB or other systemic disease.
- Subject is currently pregnant or lactating.
- Subject had surgery within 30 days prior to enrollment
- Subject has known allergy to benzalkonium chloride.
- Subject participated in an investigational drug or device trial within 30 days prior to enrollment.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00975455
Locations
| United States, Florida | |
| Atlantic Urological Associates | |
| Daytona, Florida, United States, 32114 | |
| Winter Park Urology | |
| Orlando, Florida, United States, 32803 | |
| United States, Indiana | |
| Metropolitan Urology | |
| Jeffersonville, Indiana, United States, 47130 | |
| United States, Minnesota | |
| Mayo Validation Support Services | |
| Rochester, Minnesota, United States, 55905 | |
| United States, New Jersey | |
| Coastal Urology Associates | |
| Brick, New Jersey, United States, 08723 | |
| Associates in Urology | |
| Orange, New Jersey, United States, 07052 | |
| United States, New York | |
| Community Care Physicians | |
| Albany, New York, United States, 12208 | |
| Hudson Valley Urology | |
| Poughkeepsie, New York, United States, 12601 | |
| United States, North Carolina | |
| Eastern Urological Associates | |
| Greenville, North Carolina, United States, 27834 | |
| United States, Ohio | |
| The Urology Group | |
| Cincinnati, Ohio, United States, 45212 | |
| United States, South Carolina | |
| Carolina Urologic Research Center | |
| Myrtle Beach, South Carolina, United States, 29572 | |
| United States, Texas | |
| Urology Clinics of North Texas | |
| Dallas, Texas, United States, 75231 | |
| Urology San Antonio Research | |
| San Antonio, Texas, United States, 78229 | |
Sponsors and Collaborators
Predictive Biosciences
More Information
No publications provided
| Responsible Party: | Ellen Sheets, MD, Predictive Biosciences |
| ClinicalTrials.gov Identifier: | NCT00975455 History of Changes |
| Other Study ID Numbers: | PBS-002 |
| Study First Received: | September 10, 2009 |
| Last Updated: | June 7, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Hematuria Urination Disorders Urologic Diseases Hemorrhage Pathologic Processes |
ClinicalTrials.gov processed this record on June 18, 2013